Annovis Prices $21M Stock-and-Warrant Offering at $1.00, a Premium to the $0.87 Market Price
ANVS is trading near its 52-week low of $0.93 (6.5% below the low).
Summary
Annovis priced a $21.0M underwritten offering of 19.0M shares (or pre-funded warrants for up to 2.0M shares), each unit paired with a warrant for up to 21.0M shares exercisable at $1.00. The $1.00 unit price sits above the $0.8689 market price, so the deal is not a deep discount — but it roughly doubles the share count on a company with a market cap near $52M, and the 21.0M warrants add a second layer of dilution if exercised. This follows the Nov. 4 launch announcement and the same-day 8-K disclosing only about $2.8M of cash as of September 30, plus the Oct. 29 NYSE notice that the 30-day average market cap fell below the $50M continued-listing threshold. The raise buys runway for the Phase 3 buntanetap program but does little to fix the listing problem. Closing is expected on or about Nov. 6, 2026, subject to customary conditions.
At the time of this announcement, ANVS was trading at $0.87 on NYSE in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.93 to $5.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.